Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Announcement of the Result of Phase III Clinical Trial of KP-001 in Japan
[Summary] Consolidated Financial Results for the Six-Months Period of Fiscal 2025 (Six-Month Period Ended September 30, 2025) [JGAAP]
Revision to Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2026
Approval for Marketing Authorization for Efinaconazole in Germany for the Treatment of Onychomycosis
Approval for Marketing Authorization for ECCLOCK gel 5% in Korea for Treatment of Primary Axillary Hyperhidrosis
[Summary] Consolidated Financial Results for the Three Months Period of Fiscal 2025 (Three Month Period Ended June 30, 2025) [JGAAP]
Strategic Collaboration with Astria Therapeutics, Inc. to Develop and Commercialize Navenibart for Hereditary Angioedema in Japan
License Agreement for “gMSC1”, the Allogenic Synovial Mesenchymal Stem Cell-Derived Three-Dimensional Artificial Tissue
Notice Regarding Completion of Cancellation of Treasury Shares
Notice of Implementation of Share Benefit Rules and Disposal of Treasury Stock by Third-Party Allotment
[Summary]Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 [JGAAP]
Notice Regarding Differences Between Non-Consolidated Financial Results and Results for the Previous Fiscal Year
Updates on Actions to Implement Management that is Conscious of Cost of Capital and Stock Price
Notice Regarding Completion of Acquisition of Treasury Shares
Partnership and License Agreement for the Commercialization of Sebetralstat for Hereditary Angioedema in Japan
Partial Revision of Long-Term Business Plan 2031
Revision to Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2025
Notice Regarding Acquisition of Treasury Shares
[Summary]Consolidated Financial Results for the Nine-Months Period of Fiscal 2024 (Nine-Month Period Ended December 31, 2024) [JGAAP]
[Summary]Consolidated Financial Results for the Six-Months Period of Fiscal 2024 (Six-Month Period Ended September 30, 2024) [JGAAP]